Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilya G Glezerman

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Kidney360|April 4, 2022
Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: CONVictoria Gutgarts, Ilya G Glezerman
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 16, 2019
Kidney Complications of Immune Checkpoint Inhibitors: A ReviewRoman Shingarev, Ilya G Glezerman
Advances in Chronic Kidney Disease|August 6, 2017
Kidney Toxicities Associated With Novel Cancer TherapiesJoannie Lefebvre, Ilya G Glezerman
Therapeutics and Clinical Risk Management|December 18, 2015
Hypercalcemia of malignancy and new treatment optionsHillel Sternlicht, Ilya G Glezerman
NDT Plus|May 19, 2015
Reversible Fanconi syndrome due to lenalidomideIlya G Glezerman, Tarun Kewalramani, Kenar Jhaveri
Journal of the National Cancer Institute|June 8, 2014
ResponseIlya G Glezerman, Mimi I Hu, Rajul K Jain
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 19, 2011
Kidney tubular toxicity of maintenance pemetrexed therapyIlya G Glezerman, M Catherine Pietanza, Vincent Miller, et al.
Nephron. Clinical Practice|November 6, 2010
Nephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literatureKenar D Jhaveri, Carlos D Flombaum, Glenn Kroog, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 17, 2016
Paraprotein-Related Kidney Disease: Diagnosing and Treating Monoclonal Gammopathy of Renal SignificanceMitchell H Rosner, Amaka Edeani, Motoko Yanagita, et al.
Hypertension (Dallas, Tex. : 1979)|July 26, 2017
Hypertension and VEGF (Vascular Endothelial Growth Factor) Receptor Tyrosine Kinase Inhibition: Effects on Renal FunctionBrian C Boursiquot, Emily C Zabor, Ilya G Glezerman, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Kidney360|April 4, 2022
Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: CONVictoria Gutgarts, Ilya G Glezerman
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 16, 2019
Kidney Complications of Immune Checkpoint Inhibitors: A ReviewRoman Shingarev, Ilya G Glezerman
Advances in Chronic Kidney Disease|August 6, 2017
Kidney Toxicities Associated With Novel Cancer TherapiesJoannie Lefebvre, Ilya G Glezerman
Therapeutics and Clinical Risk Management|December 18, 2015
Hypercalcemia of malignancy and new treatment optionsHillel Sternlicht, Ilya G Glezerman
NDT Plus|May 19, 2015
Reversible Fanconi syndrome due to lenalidomideIlya G Glezerman, Tarun Kewalramani, Kenar Jhaveri
Journal of the National Cancer Institute|June 8, 2014
ResponseIlya G Glezerman, Mimi I Hu, Rajul K Jain
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 19, 2011
Kidney tubular toxicity of maintenance pemetrexed therapyIlya G Glezerman, M Catherine Pietanza, Vincent Miller, et al.
Nephron. Clinical Practice|November 6, 2010
Nephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literatureKenar D Jhaveri, Carlos D Flombaum, Glenn Kroog, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 17, 2016
Paraprotein-Related Kidney Disease: Diagnosing and Treating Monoclonal Gammopathy of Renal SignificanceMitchell H Rosner, Amaka Edeani, Motoko Yanagita, et al.
Hypertension (Dallas, Tex. : 1979)|July 26, 2017
Hypertension and VEGF (Vascular Endothelial Growth Factor) Receptor Tyrosine Kinase Inhibition: Effects on Renal FunctionBrian C Boursiquot, Emily C Zabor, Ilya G Glezerman, et al.
Pageof 3